- Home
- CYRX vs ADCT Comparison
CYRX vs ADCT Comparison
Compare CYRX & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- ADCT
- Stock Information
- Founded
- CYRX 1999
- ADCT 2011
- Country
- CYRX United States
- ADCT Switzerland
- Employees
- CYRX N/A
- ADCT N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- CYRX Health Care
- ADCT Health Care
- Exchange
- CYRX Nasdaq
- ADCT Nasdaq
- Market Cap
- CYRX 277.5M
- ADCT 241.0M
- IPO Year
- CYRX N/A
- ADCT 2020
- Fundamental
- Price
- CYRX $6.37
- ADCT $2.78
- Analyst Decision
- CYRX Strong Buy
- ADCT Strong Buy
- Analyst Count
- CYRX 8
- ADCT 6
- Target Price
- CYRX $10.75
- ADCT $7.80
- AVG Volume (30 Days)
- CYRX 467.6K
- ADCT 937.9K
- Earning Date
- CYRX 08-05-2025
- ADCT 08-05-2025
- Dividend Yield
- CYRX N/A
- ADCT N/A
- EPS Growth
- CYRX N/A
- ADCT N/A
- EPS
- CYRX N/A
- ADCT N/A
- Revenue
- CYRX $232,134,000.00
- ADCT $75,817,000.00
- Revenue This Year
- CYRX N/A
- ADCT $10.65
- Revenue Next Year
- CYRX $9.63
- ADCT $15.05
- P/E Ratio
- CYRX N/A
- ADCT N/A
- Revenue Growth
- CYRX 11.75
- ADCT 10.49
- 52 Week Low
- CYRX $4.58
- ADCT $1.05
- 52 Week High
- CYRX $9.93
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- CYRX 48.30
- ADCT 47.62
- Support Level
- CYRX $6.53
- ADCT $3.21
- Resistance Level
- CYRX $6.98
- ADCT $3.97
- Average True Range (ATR)
- CYRX 0.47
- ADCT 0.38
- MACD
- CYRX -0.01
- ADCT -0.12
- Stochastic Oscillator
- CYRX 56.38
- ADCT 3.43
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).